Piramal spends £55m to bolster its UK manufacturing presence
The investment covers two expansions to accommodate several pipeline products moving to commercial scale
CDMO Piramal Pharma Solutions has laid out plans to increase its UK presence by investing approximately £55 million at its Grangemouth (Scotland) and Morpeth (England) facilities.
The company has said it will be expanding antibody-drug conjugate (ADC) capabilities at Grangemouth and upgrading the API infrastructure at Morpeth.
Not only will this investment enhance Piramal's s drug development and manufacturing capabilities in the UK, it will also increase new employment opportunities for technical and operational staff.
Specifically, two new ADC manufacturing suites, which the company expects will be up and running by Q3 2023, will be added to the existing three to significantly expand Piramal's ADC capacity at this site.
The building has been designed to accommodate further expansion, with planned future phases that include a new sterile fill/finish suite dedicated to ADCs and two additional large-scale manufacturing suites capable of handling increased batch sizes.
The company says it is also constructing a new customer experience center for clients who are visiting the site during development and/or manufacturing activities. Ground preparation and piling works are alreadt well under way.
The new facility will be fully supported by analytical laboratories (QC, cell-based assay and ELISA, GMP), warehousing, and administrative offices, all housed in a purpose-built facility.
Piramal Pharma Solutions' CEO Peter DeYoung cited demand for commercial ADCs as well as a "strong pipeline for clinical materials" as the main drivers behind doubling the company's ADC production capacity at Grangemouth.
The price tag for the Grangemouth expansion, which is being built on a 5-acre brownfield plot less than 100 m from the existing site, accounts for £45 million, including £2.4-million grant from Scottish Enterprise, Scotland's national economic development agency, as well as client co-funding.
The approximately £10 million investment in API capabilities at the company's Morpeth site, will include new equipment, infrastructure, and utility systems to meet increased market demand from global API customers.
At the same time, by replacing obsolete equipment with new, energy-efficient alternatives, Piramal will also improve its carbon footprint.
Related News
-
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance